Alkermes (ALKS) Other financing activities (2010 - 2026)
Alkermes' (ALKS) quarterly Other financing activities came in at $15.7 million in Q1 2026, down 46.78% year-on-year from $29.5 million in Q1 2025, and up 40.58% on a QoQ basis from $11.2 million in Q4 2025.
Alkermes (ALKS) Other financing activities (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Other financing activities data on file, last reported at $15.7 million in Q1 2026.
- On a quarterly basis, Other financing activities fell 46.78% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $29.6 million, a 35.48% decrease from a year earlier, with the FY2025 full-year figure at $43.4 million, up 57.45% from the prior year.
- Other financing activities for Q1 2026 stood at $15.7 million, up from $11.2 million in the prior quarter.
- Over the last five years, Other financing activities for ALKS reached as high as $29.5 million in Q1 2025 and fell as low as $622000.0 in Q3 2025.
- Historically, Other financing activities has averaged $7.2 million across 5 years, with a median of $3.1 million in 2023.
- Across the five-year window, Other financing activities surged 398.97% in 2024 and sank 88.73% in 2025, its largest moves.
- Year by year, Other financing activities stood at $780000.0 in 2022, then soared by 111.15% to $1.6 million in 2023, then surged by 398.97% to $8.2 million in 2024, then soared by 36.02% to $11.2 million in 2025, then soared by 40.58% to $15.7 million in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $15.7 million in Q1 2026, $11.2 million in Q4 2025, and $622000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.71 Mn |
| Mar 31, 2026 | 15.71 Mn |
| Dec 31, 2025 | 11.18 Mn |
| Dec 31, 2025 | 11.18 Mn |
| Sep 30, 2025 | 622,000.00 |
| Sep 30, 2025 | 622,000.00 |
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 8.22 Mn |
| Dec 31, 2024 | 8.22 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Dec 31, 2023 | 1.65 Mn |